Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.

Jenny Nguy,Sarah A Hitchen,Nick S R Lan,Girish Dwivedi,Robert Larbalestier,Bu B Yeap,P Gerry Fegan

Internal medicine journal（2022）

引用 2|浏览13

暂无评分

摘要

Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i therapy using current Australian eligibility criteria.

查看译文

关键词

PCSK9 inhibitor,cardiovascular disease,coronary artery bypass graft,dyslipidaemia,low-density lipoprotein cholesterol,statin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要